TTP-8307 是几种鼻和肠道病毒 (rhino-/enteroviruses) 复制的有效抑制剂。TTP-8307 通过干扰病毒 RNA 的合成抑制 coxsackievirus B3 病毒 (CVB3; EC₅₀=1.2 μM) 和 poliovirus 病毒。TTP-8307 通过氧化甾醇结合蛋白 (OSBP) 发挥抗病毒活性。

TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC 50 =1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP).

Solid

TTP-8307 targets the nonstructural protein 3A, inhibits the replication of coxsackievirus B3 (CVB3 Nancy) with EC50 of 1.2 μM. TTP-8307 inhibits the replication of coxsackievirus B3 and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (EC50 of 0.85 and 5.34 μM). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
TTP-8307 inhibits OSBP-dependent viruses encephalomyocarditis virus (EMCV) and HCV. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. De Palma AM, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53(5):1850-7.
[2]. Albulescu L, et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44.

In Vitro: DMSO : 100 mg/mL (229.11 mM; Need ultrasonic)配制储备液